Adli, M., C. Baethge, A. Heinz, N. Langlitz and M. Bauer (2005). "Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 255 (6): 387-400
Ali, M. K. and R. W. Lam (2011). Comparative efficacy of escitalopram in the treatment of major depressive disorder. Neuropsychiatr Dis Treat 7: 39-49
Bauer, M., P. Tharmanathan, H. P. Volz, H. J. Moeller and N. Freemantle (2009). The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur Arch Psychiatry Clin Neurosci 259 (3): 172-185
Berlim, M. T. and G. Turecki (2007). "What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials. Eur Neuropsychopharmacol 17 (11): 696-707
Bielski, R. J., D. Ventura and C. C. Chang (2004). A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 65 (9): 1190-1196
Bose, A., J. Tsai and D. Li (2012). Early non-response in patients with severe depression: escitalopram up-titration versus switch to duloxetine. Clin Drug Investig 32 (6): 373-385
Bschor, T. and C. Baethge (2010). No evidence for switching the antidepressant: systematic review and meta-analysis of RCTs of a common therapeutic strategy. Acta Psychiatr Scand 121 (3): 174-179
Burke, W. J., I. Gergel and A. Bose (2002). Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 63 (4): 331-336
Chen, Y. M., X. M. Huang, R. Thompson and Y. B. Zhao (2011). Clinical features and efficacy of escitalopram treatment for geriatric depression. J Int Med Res 39 (5): 1946-1953
CHMP (2002). Note for guidance on clinical investigation of medicinal products in the treatment of depression. http://www.emea.europa.eu/pdfs/human/ewp/051897en.pdf
Cipriani, A., T. A. Furukawa, G. Salanti, J. R. Geddes, J. P. Higgins, R. Churchill, et al. (2009). Comparative efficacy and acceptability of 12 new-generation antidepressants: a multipletreatments meta-analysis. Lancet 373(9665): 746-758
Cipriani, A., C. Santilli, T. A. Furukawa, A. Signoretti, A. Nakagawa, H. McGuire, et al. (2009). Escitalopram versus other antidepressive agents for depression." Cochrane Database Syst Rev(2): CD006532
Committee for Medicinal Products for Human Use (2002). Note for guidance on clinical investigation of medicinal products in the treatment of depression. http://www.emea.europa.eu/pdfs/ human/ewp/051897en.pdf
Committee for Medicinal Products for Human Use. (2013). Guideline on clinical investigation of medicinal products in the treatment of depression. Retrieved 30/09/2014, 2014, from http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2013/05/WC500143770.pdf
Corya, S. A., D. Williamson, T. M. Sanger, S. D. Briggs, M. Case and G. Tollefson (2006). A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 23 (6): 364-372
de Montigny, C., P. H. Silverstone, G. Debonnel, P. Blier and D. Bakish (1999). Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial. J Clin Psychopharmacol 19 (5): 401-406
Fang, Y., C. Yuan, Y. Xu, J. Chen, Z. Wu, L. Cao, et al. (2010). Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population. J Clin Psychopharmacol 30 (4): 357-364
Fava, M. (2003). Diagnosis and defi nition of treatment-resistant depression. Biol Psychiatry 53 (8): 649-659
Gaynes, B. N., S. B. Dusetzina, A. R. Ellis, R. A. Hansen, J. F. Farley, W. C. Miller, et al. (2012). Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR∗D. J Clin Psychopharmacol 32 (1): 114-119
Guy, W. (1976). ECDEU Assessment manual for psychopharmacology: revised. Rockville, MD
Hamilton, M. (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62
Kasper, S., D. S. Baldwin, S. Larsson Lonn and J. P. Boulenger (2009). Superiority of escitalopram to paroxetine in the treatment of depression. Eur Neuropsychopharmacol 19 (4): 229-237
Kasper, S., J. Sacher, N. Klein, N. Mossaheb, T. Attarbaschi-Steiner, R. Lanzenberger, et al. (2009). Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram. Int Clin Psychopharmacol 24 (3): 119-125
Kennedy, S. H., H. F. Andersen and M. E. Thase (2009). Escitalopram in the treatment of major depressive disorder: a metaanalysis. Curr Med Res Opin 25 (1): 161-175
Kilts, C. D., A. G. Wade, H. F. Andersen and T. E. Schlaepfer (2009). Baseline severity of depression predicts antidepressant drug response relative to escitalopram. Expert Opin Pharmacother 10 (6): 927-936
Kirino, E. (2012). Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability. Patient Prefer Adherence 6: 853-861
Kornstein, S. G., D. Li, Y. Mao, S. Larsson, H. F. Andersen and G. I. Papakostas (2009). Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: integrative analysis of four double-blind, randomized clinical trials. CNS Spectr 14 (6): 326-333
Lam, R. W., S. L. Lonn and N. Despiegel (2010). Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis. Int Clin Psychopharmacol 25 (4): 199-203
Laux, G., M. Friede and W. E. Muller (2013). Treatment of comorbid anxiety and depression with escitalopram: results of a post-marketing surveillance study. Pharmacopsychiatry 46 (1): 16-22
Leonard, B. and D. Taylor (2010). Escitalopram-translating molecular properties into clinical benefi t: reviewing the evidence in major depression. J Psychopharmacol 24 (8): 1143-1152
Licht, R. W. and S. Qvitzau (2002). "Treatment strategies in patients with major depression not responding to fi rst-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology (Berl) 161 (2): 143-151
Lingjaerde, O., U. G. Ahlfors, P. Bech, S. J. Dencker and K. Elgen (1987). "The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334: 1-100
Mbaya, P. (2002). Safety and efficacy of high dose of venlafaxine XL in treatment resistant major depression. Hum Psychopharmacol 17 (7): 335-339
Montgomery, S. and M. Asberg (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134: 382-389
Montgomery, S., T. Hansen and S. Kasper (2011). Efficacy of escitalopram compared to citalopram: a meta-analysis. Int J Neuropsychopharmacol 14 (2): 261-268
Montgomery, S. A. and H. F. Andersen (2006). Escitalopram versus venlafaxine XR in the treatment of depression. Int Clin Psychopharmacol 21 (5): 297-309
Power, R. A., B. Muthen, N. Henigsberg, O. Mors, A. Placentino, J. Mendlewicz, et al. (2012). Non-random dropout and the relative efficacy of escitalopram and nortriptyline in treating major depressive disorder. J Psychiatr Res 46 (10): 1333-1338
Rapaport, M. H., G. M. Gharabawi, C. M. Canuso, R. A. Mahmoud, M. B. Keller, C. A. Bossie, et al. (2006). Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 31 (11): 2505-2513
Ruhe, H. G., J. Huyser, J. A. Swinkels and A. H. Schene (2006). Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 67 (12): 1836-1855
Rush, A. J., M. H. Trivedi, S. R. Wisniewski, J. W. Stewart, A. A. Nierenberg, M. E. Thase, et al. (2006). Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 354 (12): 1231-1242
Saiz-Ruiz, J., A. Ibanez, M. Diaz-Marsa, F. Arias, J. Padin, M. Martin-Carrasco, et al. (2002). Efficacy of venlafaxine in major depression resistant to selective serotonin reuptake inhibitors. Prog Neuropsychopharmacol Biol Psychiatry 26 (6): 1129-1134
Sanchez, C., E. H. Reines and S. A. Montgomery (2014). A comparative review of escitalopram, paroxetine, and sertraline: are they all alike? Int Clin Psychopharmacol 29 (4): 185-196
Schweitzer, I., G. Burrows, V. Tuckwell, A. Polonowita, P. Flynn, T. George, et al. (2001). Sustained response to open-label venlafaxine in drug-resistant major depression. J Clin Psychopharmacol 21 (2): 185-189
Sheehan, D. V. (1983). The Anxiety Disease. New York, Charles Scribner & Sons
Signorovitch, J., K. Ramakrishnan, R. Ben-Hamadi, A. P. Yu, E. Q. Wu, H. Dworak, et al. (2011). Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors. Curr Med Res Opin 27 (6): 1089-1096
Souery, D., J. Amsterdam, C. de Montigny, Y. Lecrubier, S. Montgomery, O. Lipp, et al. (1999). Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol 9 (1-2): 83-91
Souery, D., P. Oswald, I. Massat, U. Bailer, J. Bollen, K. Demyttenaere, et al. (2007). Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry 68 (7): 1062-1070
Souery, D., A. Serretti, R. Calati, P. Oswald, I. Massat, A. Konstantinidis, et al. (2011). Switching antidepressant class does not improve response or remission in treatment-resistant depression. J Clin Psychopharmacol 31 (4): 512-516
Souery, D., A. Serretti, R. Calati, P. Oswald, I. Massat, A. Konstantinidis, et al. (2011). "Citalopram versus desipramine in treatment resistant depression: Effect of continuation or switching strategies. A randomized open study. World J Biol Psychiatry 12 (5): 364-375
Stahl, S. M., R. Entsuah and R. L. Rudolph (2002). Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol Psychiatry 52 (12): 1166-1174
Stamouli, S. S., A. Yfantis, E. Lamboussis, A. Liakouras, V. Lagari, M. Tzanakaki, et al. (2009). Escitalopram in clinical practice in Greece: treatment response and tolerability in depressed patients. Expert Opin Pharmacother 10 (6): 937-945
Thase, M. E. (2001). The need for clinically relevant research on treatment-resistant depression. J Clin Psychiatry 62 (4): 221-224
Wade, A. G., G. M. Crawford and A. Yellowlees (2011). Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study. BMC Psychiatry 11: 42
Zhong, H., N. Haddjeri and C. Sanchez (2012). Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter-a review of current understanding of its mechanism of action. Psychopharmacology (Berl) 219 (1): 1-13
